• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-12

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin probe for visualizing α-D-glucose and α-D-mannose residues on cell surfaces, tissue sections, and other glycoprotein-rich samples. It is suited to immunofluorescence, flow cytometry, and glycobiology workflows, but should not be interpreted as a universal glycan stain or used outside validated carbohydrate-binding assays.

• ECL Chemiluminescent Substrate Detection Kit Workflow

  2026-08-12

  Apply hypersensitive HRP chemiluminescence to low-abundance immunoblots, including mitochondrial and ER-remodeling studies in trigeminal neuron–glia models. This workflow combines extended signal availability, low background, and practical exposure strategies for reliable protein detection on nitrocellulose or PVDF membranes.

• Dovitinib (TKI-258) Cancer Research Workflows

  2026-08-11

  Build reproducible RTK-inhibition experiments with Dovitinib across hematologic and solid-tumor models, while separating pathway suppression from nonspecific toxicity. This workflow connects dose-response testing, ERK/STAT readouts, apoptosis assays, and immune-signature profiling for more informative translational studies.

• BIRC2 and BIRC3 Regulation in Pulmonary Epithelium

  2026-08-11

  Thorne et al. show that inflammatory cytokines and glucocorticoids regulate BIRC2 and BIRC3 differently in pulmonary epithelial models. The work identifies BIRC3 as a strongly inducible, potentially protective response, while relatively stable BIRC2 may support rapid signaling functions.

• Gramine Drives Ferroptosis in TNBC via CUL3–MTDH

  2026-08-10

  This study identifies a CUL3–MTDH ubiquitination pathway through which the natural indole alkaloid gramine suppresses triple-negative breast cancer by promoting ferroptosis. Its combination of target-engagement assays, ferroptosis rescue experiments, genetic perturbation, and xenograft validation provides a mechanistic framework for evaluating gramine as a candidate strategy in chemoresistant TNBC.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-09

  Masitinib (AB1010) is a DMSO-compatible kinase inhibitor for research involving KIT, PDGFRα, PDGFRβ, mast cell responses, and selected KIT-mutant cell models. It is not appropriate for aqueous or ethanol-based workflows, broad-spectrum kinase screening, or direct clinical use without separately validated evidence.

• Inonotus hispidus Polypeptide in Periodontitis

  2026-08-08

  A January 2025 study found that a purified polypeptide fraction from Inonotus hispidus combined antibacterial, anti-inflammatory, microbiome-associated, and bone-protective effects across cellular, animal, and human investigations. Its findings implicate β-catenin/NF-κB signaling as a possible mechanism for limiting inflammatory alveolar bone loss, while also highlighting the need for more detailed translational validation.

• Roscovitine (Seliciclib) and Tumor Immunity

  2026-08-07

  Roscovitine (Seliciclib, CYC202) offers translational researchers a defined way to interrogate CDK-driven cell-cycle control alongside radiotherapy and checkpoint blockade. This article separates established evidence from forward-looking hypotheses and outlines how to evaluate cell-cycle arrest, tumor control, immune remodeling, and experimental readiness.

• Meta-Analysis: Azilsartan Medoxomil Monopotassium in BP Redu

  2026-08-07

  This systematic review and network meta-analysis rigorously assessed the efficacy of azilsartan medoxomil (TAK 491) against other antihypertensive agents in lowering blood pressure among mild-to-moderate hypertensive patients. The results demonstrate that azilsartan medoxomil, especially at 80 mg, outperforms other first-line treatments, providing robust evidence to inform essential hypertension treatment research.

• Modeling Human SAN-Neural Maturation with PSC-Derived Assemb

  2026-08-06

  This study establishes a human in vitro model integrating pluripotent stem cell-derived sinoatrial node and cardiac plexus assembloids, enabling the functional dissection of neuro-cardiac crosstalk during pacemaker maturation. The platform advances understanding of neuron-to-pacemaker signaling pathways critical for both physiological cardiac rhythm and conduction disease mechanisms.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Interac

  2026-08-06

  Oliveira et al. (2025) identify that naturally occurring angiotensin peptides, including fragments like H2N-Ile-His-Pro-OH, significantly enhance SARS-CoV-2 spike protein binding to the AXL receptor. This mechanistic finding bridges renin-angiotensin system research and viral pathogenesis, revealing new perspectives for both cardiovascular and COVID-19 studies.

• Phosphatase Inhibitor Cocktail 3 (100X in DMSO): Technical G

  2026-08-05

  Phosphatase Inhibitor Cocktail 3 (100X in DMSO) addresses the challenge of preserving protein phosphorylation during extraction from animal tissues or cultured cells by broadly inhibiting serine/threonine and alkaline phosphatases. It is optimal for workflows requiring accurate phosphoprotein analysis but is not suitable where dephosphorylation is a necessary analytical step.

• Inonotus hispidus Polypeptide Suppresses Inflammatory Bone L

  2026-08-05

  This study demonstrates that a purified polypeptide from Inonotus hispidus (IHP) alleviates periodontitis by targeting inflammatory bone loss mechanisms. Through antimicrobial, anti-inflammatory, and signaling pathway regulation, IHP offers a novel approach to managing this chronic oral disease with translational potential for advanced immunodetection workflows.

• Solving Organoid and EMT Assay Challenges with A 83-01 (ALK

  2026-08-04

  This article delivers scenario-driven, evidence-backed guidance for biomedical researchers and lab technicians exploring the use of A 83-01 (ALK inhibitor), SKU A3133. Drawing on recent advances in organoid systems and EMT research, we address real-world assay challenges and demonstrate how this selective ALK-5 inhibitor from APExBIO enables reproducible, high-fidelity TGF-β signaling modulation.

• Structural Insights into ASCH Domains and N4-Acetylcytidine

  2026-08-04

  Meng et al. (2025) present the first high-resolution structural analysis of ASCH domain-containing proteins, revealing the substrate specificity and catalytic mechanism of the E. coli enzyme EcYqfB in converting free N4-acetylcytidine to cytidine. These findings refine our understanding of nucleotide processing enzymes and provide a framework for advanced RNA epigenetics research.

15508 records 1/1034 page Next 12345 下5页 Last page